Table 5.
Incidence of Cholangitis and Mortality within 6 or 12 Months According to the Type of Stent
| Cholangitis and mortality | Initial EBD, HR (95% CI) | Overall EBD, HR (95% CI) | |||
|---|---|---|---|---|---|
| BMS | MPS | BMS | MPS | ||
| Incidence of cholangitis | |||||
| Crude | Reference | 2.51 (1.41–4.46) | Reference | 1.93 (1.14–3.25) | |
| Adjusted | Reference | 2.89 (1.57–5.29) | Reference | 2.08 (1.21–3.58) | |
| Mortality within 6 months | |||||
| Crude | Reference | 1.66 (0.80–3.44) | Reference | 1.89 (0.93–3.82) | |
| Adjusted | Reference | 2.63 (1.13–6.10) | Reference | 2.91 (1.26–6.71) | |
| Mortality within 12 months | |||||
| Crude | Reference | 1.07 (0.65–1.74) | Reference | 1.42 (0.87–2.31) | |
| Adjusted | Reference | 1.21 (0.65–2.28) | Reference | 1.71 (0.93–3.13) | |
Adjusted for body mass index, bismuth type (I/II, IIIa/IIIb and IV), time varying total bilirubin, PT INR, albumin and clinical stage.
EBD, endoscopic biliary drainage; HR, hazard ratio; CI, confidence interval; BMS, bilateral metal stents; MPS, multiple plastic stents; PT, prothrombin time; INR, international normalized ratio.